Want to see SE:SEDANA full AI Analyst Report?
SEDANA Stock Chart & Stats
kr10.72
-kr0.18(-1.05%)
At close: 4:00 PM EST
kr10.72
-kr0.18(-1.05%)
Day’s Range― - ―
52-Week Rangekr7.90 - kr18.32
Previous CloseN/A
Volume45.94K
Average Volume (3M)247.68K
Market Cap
kr861.25M
Enterprise Valuekr776.21M
Total Cash (Recent Filing)kr80.68M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Jul 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding99,336,960
10 Day Avg. Volume186,290
30 Day Avg. Volume247,675
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr207.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low leverage provides durable financial flexibility: the company can fund commercialization, absorb operating losses, and delay dilutive financing. A conservative capital structure reduces refinancing risk and supports multi-quarter execution on commercial expansion and regulatory initiatives.
High Gross Margins (~71%)Sustained ~71% gross margins indicate attractive unit economics from the Sedaconda product and delivery system. High product-level margins create room for investments in sales and R&D while enabling operating leverage as volumes scale, making profitability easier if revenue growth recovers.
Recurring Consumables + Proprietary PharmaceuticalA business model combining a proprietary pharmaceutical and per‑patient consumables supports recurring revenue. Consumable-driven usage in ICUs can produce repeatable demand and predictable per-patient revenue, strengthening long-term revenue visibility as clinical adoption grows.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow (~-47.8M TTM) implies ongoing cash burn and reliance on existing liquidity or new funding. Over several quarters this raises financing risk, constrains reinvestment capacity, and forces management to prioritize cash preservation over growth initiatives.
Flat-to-down Revenue TrendTop-line momentum is weak (TTM ~-2%); slow adoption or limited geographic penetration reduces the likelihood of near-term operating leverage. Without durable revenue growth, the company cannot spread fixed costs, delaying path to sustainable profitability and weakening long-term cash generation.
Persistent Negative Operating And Net MarginsMaterial negative EBIT and net margins indicate the company currently destroys equity value despite strong gross margins. Until operating expenses align with revenue or volumes scale meaningfully, the structural loss profile will erode shareholder value and require either margin improvement or additional capital.
Sedana Medical AB News
SEDANA FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was kr7.90 and its highest was kr18.32 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is kr861.25M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Jul 17, 2026 which is in 12 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Apr 23, 2026. The company reported -kr0.04 earnings per share for the quarter, beating the consensus estimate of -kr0.044 by kr0.004.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is -0.09.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -kr0.04 in its last earnings report, beating expectations of -kr0.044. Following the earnings report the stock price went down -2.302%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in SE:SEDANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---